A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines von Hollenbach, Paul W, Nguyen, Aaron N, Brady, Helen, Williams, Michelle, Ning, Yuhong, Richard, Normand, Krushel, Leslie, Aukerman, Sharon L, Heise, Carla, MacBeth, Kyle J

Volltext

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype von Sallman, David A., McLemore, Amy F., Aldrich, Amy L., Komrokji, Rami S., McGraw, Kathy L., Dhawan, Abhishek, Geyer, Susan, Hou, Hsin-An, Eksioglu, Erika A., Sullivan, Amy, Warren, Sarah, MacBeth, Kyle J., Meggendorfer, Manja, Haferlach, Torsten, Boettcher, Steffen, Ebert, Benjamin L., Al Ali, Najla H., Lancet, Jeffrey E., Cleveland, John L., Padron, Eric, List, Alan F.

Volltext

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia von Wang, Feng, Morita, Kiyomi, DiNardo, Courtney D., Furudate, Ken, Tanaka, Tomoyuki, Yan, Yuanqing, Patel, Keyur P., MacBeth, Kyle J., Wu, Bin, Liu, Guowen, Frattini, Mark, Matthews, Jairo A., Little, Latasha D., Gumbs, Curtis, Song, Xingzhi, Zhang, Jianhua, Thompson, Erika J., Kadia, Tapan M., Garcia-Manero, Guillermo, Jabbour, Elias, Ravandi, Farhad, Bhalla, Kapil N., Konopleva, Marina, Kantarjian, Hagop M., Andrew Futreal, P., Takahashi, Koichi

Volltext

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia von GARCIA-MANERO, Guillermo, GORE, Steven D, KANTARJIAN, Hagop, SKIKNE, Barry, COGLE, Christopher, WARD, Renee, TAO SHI, MACBETH, Kyle J, LAILLE, Eric, GIORDANO, Heidi, SAKOIAN, Sarah, JABBOUR, Elias

Volltext

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies von Laille, Eric, Shi, Tao, Garcia-Manero, Guillermo, Cogle, Christopher R, Gore, Steven D, Hetzer, Joel, Kumar, Keshava, Skikne, Barry, MacBeth, Kyle J

Volltext

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) von Saft, Leonie, Karimi, Mohsen, Ghaderi, Mehran, Matolcsy, András, Mufti, Ghulam J, Kulasekararaj, Austin, Göhring, Gudrun, Giagounidis, Aristoteles, Selleslag, Dominik, Muus, Petra, Sanz, Guillermo, Mittelman, Moshe, Bowen, David, Porwit, Anna, Fu, Tommy, Backstrom, Jay, Fenaux, Pierre, MacBeth, Kyle J, Hellström-Lindberg, Eva

Volltext

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS von Krönke, Jan, Fink, Emma C., Hollenbach, Paul W., MacBeth, Kyle J., Hurst, Slater N., Udeshi, Namrata D., Chamberlain, Philip P., Mani, D. R., Man, Hon Wah, Gandhi, Anita K., Svinkina, Tanya, Schneider, Rebekka K., McConkey, Marie, Järås, Marcus, Griffiths, Elizabeth, Wetzler, Meir, Bullinger, Lars, Cathers, Brian E., Carr, Steven A., Chopra, Rajesh, Ebert, Benjamin L.

Volltext

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib von Stein, Eytan M., DiNardo, Courtney D., Fathi, Amir T., Pollyea, Daniel A., Stone, Richard M., Altman, Jessica K., Roboz, Gail J., Patel, Manish R., Collins, Robert, Flinn, Ian W., Sekeres, Mikkael A., Stein, Anthony S., Kantarjian, Hagop M., Levine, Ross L., Vyas, Paresh, MacBeth, Kyle J., Tosolini, Alessandra, VanOostendorp, Jason, Xu, Qiang, Gupta, Ira, Lila, Thomas, Risueno, Alberto, Yen, Katharine E., Wu, Bin, Attar, Eyal C., Tallman, Martin S., de Botton, Stéphane

Volltext

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia von Pollyea, Daniel A., Tallman, Martin S., de Botton, Stéphane, Kantarjian, Hagop M., Collins, Robert, Stein, Anthony S., Frattini, Mark G., Xu, Qiang, Tosolini, Alessandra, See, Wendy L., MacBeth, Kyle J., Agresta, Samuel V., Attar, Eyal C., DiNardo, Courtney D., Stein, Eytan M.

Volltext

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refracto... von Santini, Valeria, Almeida, Antonio, Giagounidis, Aristoteles, Gröpper, Stefanie, Jonasova, Anna, Vey, Norbert, Mufti, Ghulam J, Buckstein, Rena, Mittelman, Moshe, Platzbecker, Uwe, Shpilberg, Ofer, Ram, Ron, Del Cañizo, Consuelo, Gattermann, Norbert, Ozawa, Keiya, Risueño, Alberto, MacBeth, Kyle J, Zhong, Jianhua, Séguy, Francis, Hoenekopp, Albert, Beach, C L, Fenaux, Pierre

Volltext

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care von Döhner, Hartmut, Dolnik, Anna, Tang, Lin, Seymour, John F., Minden, Mark D., Stone, Richard M., del Castillo, Teresa Bernal, Al-Ali, Haifa Kathrin, Santini, Valeria, Vyas, Paresh, Beach, C. L., MacBeth, Kyle J., Skikne, Barry S., Songer, Steve, Tu, Nora, Bullinger, Lars, Dombret, Hervé

Volltext

Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome von Leung, Kevin K., Nguyen, Aaron, Shi, Tao, Tang, Lin, Ni, Xiaochun, Escoubet, Laure, MacBeth, Kyle J., DiMartino, Jorge, Wells, James A.

Volltext

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer von Levy, Benjamin P., Giaccone, Giuseppe, Besse, Benjamin, Felip, Enriqueta, Garassino, Marina Chiara, Domine Gomez, Manuel, Garrido, Pilar, Piperdi, Bilal, Ponce-Aix, Santiago, Menezes, Daniel, MacBeth, Kyle J., Risueño, Alberto, Slepetis, Ruta, Wu, Xiaoling, Fandi, Abderrahim, Paz-Ares, Luis

Volltext

The JAMM motif of human deubiquitinase Poh1 is essential for cell viability von Gallery, Melissa, Blank, Jonathan L, Lin, Yinghui, Gutierrez, Juan A, Pulido, Jacqueline C, Rappoli, David, Badola, Sunita, Rolfe, Mark, Macbeth, Kyle J

Volltext

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition von Harding, James J, Lowery, Maeve A, Shih, Alan H, Schvartzman, Juan M, Hou, Shengqi, Famulare, Christopher, Patel, Minal, Roshal, Mikhail, Do, Richard K, Zehir, Ahmet, You, Daoqi, Selcuklu, S Duygu, Viale, Agnes, Tallman, Martin S, Hyman, David M, Reznik, Ed, Finley, Lydia W S, Papaemmanuil, Elli, Tosolini, Alessandra, Frattini, Mark G, MacBeth, Kyle J, Liu, Guowen, Fan, Bin, Choe, Sung, Wu, Bin, Janjigian, Yelena Y, Mellinghoff, Ingo K, Diaz, Luis A, Levine, Ross L, Abou-Alfa, Ghassan K, Stein, Eytan M, Intlekofer, Andrew M

Volltext

Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia von Cathelin, Severine, Sharon, David, Subedi, Amit, Cojocari, Dan, Phillips, Darren C., Leverson, Joel D., MacBeth, Kyle J., Nicolay, Brandon, Narayanaswamy, Rohini, Ronseaux, Sebastien, Liu, Guowen, Chan, Steven M.

Volltext

Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA von MacBeth, Kyle J., Chopra, Vivek S., Tang, Lin, Zheng, Bing, Avanzino, Brian, See, Wendy L., Schwickart, Martin, Figueroa, Maria E., Quek, Lynn, DiMartino, Jorge F.

Volltext

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients von Santini, Valeria, Fenaux, Pierre, Giagounidis, Aristoteles, Platzbecker, Uwe, List, Alan F., Haferlach, Torsten, Zhong, Jim, Wu, Chengqing, Mavrommatis, Konstantinos, Beach, C. L., MacBeth, Kyle J., Almeida, Antonio

Volltext

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial von Stein, Eytan M, Fathi, Amir T, DiNardo, Courtney D, Pollyea, Daniel A, Roboz, Gail J, Collins, Robert, Sekeres, Mikkael A, Stone, Richard M, Attar, Eyal C, Frattini, Mark G, Tosolini, Alessandra, Xu, Qiang, See, Wendy L, MacBeth, Kyle J, de Botton, Stéphane, Tallman, Martin S, Kantarjian, Hagop M

Volltext

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes von Giagounidis, Aristoteles, Mufti, Ghulam J., Fenaux, Pierre, Germing, Ulrich, List, Alan, MacBeth, Kyle J.

Volltext